Steven Burrill Optimistic About Systems Biology Value Creation | GenomeWeb

One sign of the coming of a new year in the biotechnology sector is the annual release of Steven Burrill’s Biotech Outlook, which augurs the world of biotechnology for the upcoming year. BioCommerce Week caught up with Burrill, the CEO of San Francisco-based private equity firm Burrill & Co., which manages some $500 million in investment funds, to look at the emerging systems biology marketplace.

What is your outlook for ‘05?

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: mutations linked to nasopharyngeal carcinoma, salivary proteins common among oral squamous cell carcinoma patients, and more.

At Wired, a science journalist discusses her decision not to undergo BRCA testing.

The Japan Times says regulations are needed to oversee human genome-editing research.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.